Advanced Non-Small Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
- Published Date : November 2, 2025
- Updated On : May 5, 2026
- Pages : 154
Advanced Non-Small Cell Lung Cancer (NSCLC) Market Outlook
Thelansis’s “Advanced Non-Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Non-Small Cell Lung Cancer (NSCLC) Overview
Advanced non-small cell lung cancer (NSCLC) is a heterogeneous group of lung malignancies encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, representing the leading cause of cancer mortality globally, with tobacco smoking as the dominant aetiological driver alongside occupational exposures, radon, and air pollution. Comprehensive next-generation sequencing and PD-L1 immunohistochemistry are mandatory at diagnosis, identifying actionable driver mutations guiding therapeutic selection. Targetable alterations include EGFR mutations addressed with osimertinib or amivantamab-lazertinib combination, ALK rearrangements with lorlatinib as the frontline sovereign, ROS1 with entrectinib, KRAS G12C with adagrasib, MET exon 14 skipping with tepotinib, RET fusions with selpercatinib, BRAF V600E with dabrafenib-trametinib, and NTRK fusions with larotrectinib. Immunotherapy is central for driver-negative disease; pembrolizumab monotherapy is standard for high PD-L1 expressors, while chemoimmunotherapy combinations address lower expressors. Squamous cell carcinoma without targetable drivers benefits from chemoimmunotherapy combinations. Adjuvant osimertinib improves survival in resected EGFR-mutated NSCLC, while adjuvant atezolizumab addresses PD-L1-positive resected disease. Neladalkib represents the emerging fourth-generation ALK inhibitor for lorlatinib-refractory disease. Platinum-based chemotherapy retains salvage utility across unselected populations. Prognosis varies markedly with molecular subtype and stage; multidisciplinary molecular tumour board evaluation, CNS surveillance, smoking cessation, and patient-centred supportive care are integral to optimising outcomes.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Advanced Non-Small Cell Lung Cancer (NSCLC) Market Outlook
Thelansis’s “Advanced Non-Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Non-Small Cell Lung Cancer (NSCLC) Overview
Advanced non-small cell lung cancer (NSCLC) is a heterogeneous group of lung malignancies encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, representing the leading cause of cancer mortality globally, with tobacco smoking as the dominant aetiological driver alongside occupational exposures, radon, and air pollution. Comprehensive next-generation sequencing and PD-L1 immunohistochemistry are mandatory at diagnosis, identifying actionable driver mutations guiding therapeutic selection. Targetable alterations include EGFR mutations addressed with osimertinib or amivantamab-lazertinib combination, ALK rearrangements with lorlatinib as the frontline sovereign, ROS1 with entrectinib, KRAS G12C with adagrasib, MET exon 14 skipping with tepotinib, RET fusions with selpercatinib, BRAF V600E with dabrafenib-trametinib, and NTRK fusions with larotrectinib. Immunotherapy is central for driver-negative disease; pembrolizumab monotherapy is standard for high PD-L1 expressors, while chemoimmunotherapy combinations address lower expressors. Squamous cell carcinoma without targetable drivers benefits from chemoimmunotherapy combinations. Adjuvant osimertinib improves survival in resected EGFR-mutated NSCLC, while adjuvant atezolizumab addresses PD-L1-positive resected disease. Neladalkib represents the emerging fourth-generation ALK inhibitor for lorlatinib-refractory disease. Platinum-based chemotherapy retains salvage utility across unselected populations. Prognosis varies markedly with molecular subtype and stage; multidisciplinary molecular tumour board evaluation, CNS surveillance, smoking cessation, and patient-centred supportive care are integral to optimising outcomes.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)